PD-L1+ macrophages suppress T cell-mediated anticancer immunity

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-04-04 DOI:10.1080/2162402x.2024.2338951

Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp

引用次数: 0

Abstract

Recently, we showed that an autologous DC-based vaccine induces an increase in immunosuppressive PD-L1+ tumor-associated macrophages (TAM) both in the tumor and the tumor draining lymph nodes, ther...

查看原文本刊更多论文

PD-L1+ 巨噬细胞抑制 T 细胞介导的抗癌免疫力

最近，我们研究发现，基于自体DC的疫苗可诱导肿瘤和肿瘤引流淋巴结中免疫抑制性PD-L1+肿瘤相关巨噬细胞（TAM）的增加，进而诱导免疫抑制性PD-L1+肿瘤相关巨噬细胞的增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.